1-benzyl-4-piperidone profile

1-Benzyl-4-piperidone is a key intermediate in the synthesis of various pharmaceuticals, particularly those targeting the central nervous system. Its structural similarity to natural neurotransmitters like dopamine makes it a valuable tool for studying receptor interactions and pharmacological effects. Research into 1-benzyl-4-piperidone focuses on its potential as a precursor to medications for treating conditions like Parkinson's disease and depression. Its synthesis often involves the reaction of 4-piperidone with benzyl bromide, leading to the formation of the desired compound. Further modifications to the molecule can lead to the development of new drugs with improved efficacy and reduced side effects.'

1-benzyl-4-piperidone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	19220
CHEMBL ID	491630
SCHEMBL ID	4726
MeSH ID	M0510410

Synonyms (80)

Synonym
EU-0099975
AC-6376
smr001559985
NCIOPEN2_000865
1-benzylpiperidone
n-benzylpiperidin-4-one
n-benzylpiperidinone
nsc-77933
n-benzyl-4-piperidinone
1-benzyl-4-piperidone
1-benzyl-4-piperidinone
4-piperidone, 1-benzyl-
1-benzyl-4-oxopiperidine
mls002694053 ,
nsc77933
n-benzyl-4-piperidone
4-piperidone,1-benzyl
1-benzylpiperidin-4-one
inchi=1/c12h15no/c14-12-6-8-13(9-7-12)10-11-4-2-1-3-5-11/h1-5h,6-10h
4-piperidinone, 1-(phenylmethyl)-
3612-20-2
1-benzyl-4-piperidone, 99%
B1027 ,
HMS1648P07
FT-0663028
CHEMBL491630
AKOS000119701
NCGC00246875-01
399249ph5b ,
einecs 222-782-4
unii-399249ph5b
nsc 77933
FT-0688557
STL141066
BP-10640
FS-1714
SCHEMBL4726
benzyl-piperidin-4-one
4-oxo-1-benzylpiperidine
n-benzyl-4-oxopiperidine
1-(phenylmethyl)-4-piperidone
1-(phenyl-methyl)-4-piperidinone
1-benzyl4-piperidone
1-benzyl-4-oxo-piperidine
1-benzylpiperidine-4-one
1 -benzyl-4-piperidone
4-n-benzylpiperidone
1-benzyl piperidin-4-one
1-benzyl-4 -piperidone
n-benzylpiperdine-4-one
n-benzyl4-piperidone
1-benzyl -4-piperidone
benzyl-4-piperidone
1-benzylpiperid4-one
n-benzyl 4-piperidone
1-benzylpiperid-4-one
1-benzyi-4-piperidone
1-benzyl-piperidin-4-one
1-benzyl-piperid-4-one
1-phenylmethyl-4-piperidone
1-benzyl-4-piperdinone
n-benzylpiperidine-4-one
1-phenylmethyl-4-piperidinone
1-(phenylmethyl)-4-piperidinone
AM85336
Q-200108
mfcd00006192
CS-W007822
F0850-6847
DTXSID30189695
sr-01000597226
SR-01000597226-1
1-benzyl-4-piperidone, technical, >=98.0% (gc)
Z54749061
SY001468
BCP22272
EN300-16225
Q27256879
SB42971
HY-W007822

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	125.8920	5.8048	36.1306	65.1308	AID540263
snurportin-1	Homo sapiens (human)	Potency	125.8920	5.8048	36.1306	65.1308	AID540263
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID387035	Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Synthesis and potent antileukemic activities of 10-benzyl-9(10H)-acridinones.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (37.50)	29.6817
2010's	4 (50.00)	24.3611
2020's	1 (12.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
bromide Bromides: Salts of hydrobromic acid, HBr, with the bromine atom in the 1- oxidation state. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)	2.03	1	halide anion; monoatomic bromine
acridone acridone : A member of the class of acridines that is 9,10-dihydroacridine substituted by an oxo group at position 9.	2.04	1	acridines; cyclic ketone
2-piperidone 2-piperidone: structure given in first source. piperidin-2-one : A delta-lactam that is piperidine which is substituted by an oxo group at position 2.	2.03	1	delta-lactam; piperidones	EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor
piperidines Piperidines: A family of hexahydropyridines.	7.03	1

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1

1-benzyl-4-piperidone

Description

Cross-References

Synonyms (80)

Protein Targets (2)

Potency Measurements

Bioassays (14)

Research

Studies (8)

Market Indicators

Research Demand Index: 29.26

Study Types

1-benzyl-4-piperidone

Description

Cross-References

Synonyms (80)

Protein Targets (2)

Potency Measurements

Bioassays (14)

Research

Studies (8)

Market Indicators

Research Demand Index: 29.26

Study Types

Related Drugs (4)

Related Conditions (4)